Resources Blog VHH Antibodies

VHH Antibodies

Biointron 2024-01-20 Read time: 2 mins
Image credit: DOI: 10.1177/1535370219881129

Antibodies are essential tools in modern medicine and research, but not all antibodies are the same. VHH antibodies, also known as single-domain antibodies or nanobodies, are a type of antibody that offers several advantages over conventional antibodies. 

VHH antibodies are derived from the immune system of camelids, which produce antibodies that are much smaller than those produced by humans or mice. VHH antibodies consist of a single domain, or variable region, that is capable of binding to specific antigens. This makes them ideal for a wide range of applications, including diagnostic tests, therapeutics, and research tools. 

One key advantage of VHH antibodies is their small size. This allows them to penetrate tissues more effectively than larger antibodies, making them useful for targeting diseases that are difficult to reach with conventional therapies. Additionally, VHH antibodies are highly stable and can withstand harsh conditions, such as high temperatures or acidic environments, which makes them useful for a range of diagnostic and therapeutic applications. 

At Biointron, we specialize in the production of high-quality recombinant VHH antibodies for research and diagnostic purposes. Our team of experts uses state-of-the-art technologies to generate VHH antibodies that are highly specific and sensitive to their target antigens. Whether you need custom VHH antibody production or off-the-shelf options, we have the expertise to deliver the right solution for your needs. 

To learn more about our VHH antibody services, visit our website or contact us today. 

Subscribe to our Blog

Recent Blog

Computational antibody methods schematic. DOI: 10.1093/bib/bbz095The development of therapeutic antibodies has been significantly enhanced by advancements in computational methods and artificial intelligence (AI). These technologies have streamlined the antibody discovery process, improving the abil

May 27, 2024

Welcometo Antibody Basics by Biointron,Part 8. In this episode, we’ll talk about therapeutics targeting cancer.What is cancer immunotherapy?Cancer immunotherapy leverages the body's immune system to fight cancer more selectively and effectively than traditional methods such as chemotherapy

May 24, 2024

The generation of an immune response to a vaccine. DOI: 10.1038/s41577-020-00479-7Vaccination is one of the most effective tools in preventing infectious diseases. At its core, the success of a vaccine hinges on its ability to induce a robust and lasting antibody response against a specific pathogen

May 22, 2024

Innovation orientation and goals for transforming CAR-T cell engineering. DOI: 10.1186/s13045-020-00910-5Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment in which engineered CARs redirect lymphocytes, typically T cells, to recognize and destroy cells expressing a sp

May 20, 2024

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.